Together, these results indicate that TGFBR1 inhibition may be a novel therapeutic target for tumor treatment, consistent with previous results showing that downregulation of TGFBR1 suppresses cell proliferation, migration, and invasion in NSCLC [44]. This evidence concerns the gene TGFBR1 and non-small cell lung carcinoma.